Sequential Raises $3.5M to Build AI Discovery Platform for Skin Health

Sequential has raised $3.5 million in its first equity round to build an AI-powered discovery platform for multi-omic testing and next-generation skin health ingredients, announced in a press release. The round was co-led by Sparkfood and Corundum Systems Biology Inc., with participation from Dermazone Holdings, SOSV, Scrum Ventures, and others, alongside support from Innovate UK.

The Cambridge-based company has now raised a total of $7.5 million in both dilutive and non-dilutive funding. Sequential’s proprietary non-invasive testing platform quantifies how ingredients and products affect microbial and host biomarkers, enabling the creation of data-backed formulations in the personal care and biotech sectors.

The new capital will fund the development of an AI-driven discovery engine built on Sequential’s clinical dataset, which includes over 50,000 samples and 10,000 participants worldwide. This engine aims to predict and optimize bioactive ingredient combinations for skin health applications.

Sequential operates laboratories in Cambridge, New York City, and Singapore, and continues to expand its biomarker discovery programs and global partnerships to advance data-driven innovation in dermatological and personal care research.